NCT00999804 - Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy | Biotech Hunter

Enrollment

128

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

November 30, 2014

Study Completion Date

January 31, 2026

Conditions

Breast Cancer

Interventions

DRUG

Lapatinib

1000 mg of Lapatinib by mouth daily

DRUG

Letrozole

Letrozole, 2.5 mg by mouth daily (for hormone receptor positive participants only)

DRUG

Trastuzumab

6 mg/kg intravenously, every 3 weeks

Trial Locations (8)

Johns Hopkins, Baltimore

Duke University, Durham

University of Alabama - Birmingham, Birmingham

Vanderbilt University Medical Center, Nashville

Indiana University, Indianapolis

University of Chicago, Chicago

Baylor College of Medicine Lester and Sue Smith Breast Center, Houston

Dana Farber Cancer Institute, Boston